ARHGAP17 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-ARHGAP17 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityARHGAP17
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman. predicted: mouse, rat
Isotypen/a
Formataffinity purified
Size0.1 mg
Concentration100ug/100ul
ApplicationsELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionRICH1 is a GTPase-activating protein (GAP). GAPs stimulate the intrinsic GTP hydrolysis of small G proteins, such as RHOA (MIM 165390), RAC1 (MIM 602048), and CDC42 (MIM 116952).[supplied by OMIM, Apr 2004]
ImmunogenImmunogen: Rabbit polyclonal ARHGAP17 (1) antibody was raised against a recombinated human ARHGAP17 protein 2-195aa (BC080195).
Other Names[Homo sapiens Rho GTPase activating protein 17, mRNA; Rho GTPase-activating protein 17; rho GTPase-activating protein 17; RhoGAP interacting with CIP4 homologs 1; neuron-associated developmentally regulated protein; rho-type GTPase-activating protein 17; Rho GTPase activating protein 17; Rho-type GTPase-activating protein 17; RhoGAP interacting with CIP4 homologs protein 1; RICH-1], [ARHGAP17; ARHGAP17; PP367; RICH1; WBP15; MST066; MST110; NADRIN; PP4534; RICH-1; MSTP038; MSTP066; MSTP110]
Gene, Accession #[ARHGAP17], Gene ID: 55114, NCBI: BC080195
Catalog #MBS416166
Price$230
Order / More InfoARHGAP17 Antibody from MYBIOSOURCE INC.
Product Specific References(1) Wells,C.D., Fawcett,J.P., Traweger,A., et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 125 (3), 535-548 (2006).
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.